Patents by Inventor Fang-Yu Lee
Fang-Yu Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11973129Abstract: A method for forming a semiconductor device structure is provided. The semiconductor device includes forming nanowire structures stacked over a substrate and spaced apart from one another, and forming a dielectric material surrounding the nanowire structures. The dielectric material has a first nitrogen concentration. The method also includes treating the dielectric material to form a treated portion. The treated portion of the dielectric material has a second nitrogen concentration that is greater than the first nitrogen concentration. The method also includes removing the treating portion of the dielectric material, thereby remaining an untreated portion of the dielectric material as inner spacer layers; and forming the gate stack surrounding nanowire structures and between the inner spacer layers.Type: GrantFiled: March 13, 2023Date of Patent: April 30, 2024Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD.Inventors: Han-Yu Lin, Chansyun David Yang, Fang-Wei Lee, Tze-Chung Lin, Li-Te Lin, Pinyen Lin
-
Publication number: 20240111337Abstract: An electronic device including a body and a receptacle connector is provided. The body has a side wall surface, a receptacle slot located at the side wall surface, a waterproof protrusion protruding from the side wall surface, and two gutters located at the side wall surface, where the waterproof protrusion is located above the receptacle slot, and the two gutters are respectively located at two opposite sides of the receptacle slot. The receptacle connector is disposed in the receptacle slot.Type: ApplicationFiled: May 8, 2023Publication date: April 4, 2024Applicant: Acer IncorporatedInventors: Wei-Chih Wang, Chen-Min Hsiu, Chien-Yu Lee, Szu-Wei Yang, Fang-Ying Huang
-
Publication number: 20240097011Abstract: A method includes forming a fin structure over a substrate, wherein the fin structure comprises first semiconductor layers and second semiconductor layers alternately stacked over a substrate; forming a dummy gate structure over the fin structure; removing a portion of the fin structure uncovered by the dummy gate structure; performing a selective etching process to laterally recess the first semiconductor layers, including injecting a hydrogen-containing gas from a first gas source of a processing tool to the first semiconductor layers and the second semiconductor layers; and injecting an F2 gas from a second gas source of the processing tool to the first semiconductor layers and the second semiconductor layers; forming inner spacers on opposite end surfaces of the laterally recessed first semiconductor layers of the fin structure; and replacing the dummy gate structure and the first semiconductor layers with a metal gate structure.Type: ApplicationFiled: December 1, 2023Publication date: March 21, 2024Applicants: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD., TSMC NANJING COMPANY LIMITEDInventors: Han-Yu LIN, Fang-Wei LEE, Kai-Tak LAM, Raghunath PUTIKAM, Tzer-Min SHEN, Li-Te LIN, Pinyen LIN, Cheng-Tzu YANG, Tzu-Li LEE, Tze-Chung LIN
-
Patent number: 10137126Abstract: A method of preparing a very slightly soluble drug with solid composition includes the following steps: (a) adding a very slightly soluble drug into an organic solvent and polysorbate to form a first solution; (b) adding the first solution into a second solution and a pharmaceutically acceptable excipient, wherein the second solution comprises water or SLS, and a volume ratio of the first solution and the second solution is between 8:1 and 1:1; and (c) drying and compressing the mixture in step (b) to form a very slightly soluble drug with solid composition.Type: GrantFiled: March 28, 2016Date of Patent: November 27, 2018Assignee: YUNG SHIN PHARM. IND. CO., LTD.Inventors: Fang-Yu Lee, Fu-Yung Lin
-
Publication number: 20160375018Abstract: A method of preparing a very slightly soluble drug with solid composition includes the following steps: (a) adding a very slightly soluble drug into an organic solvent and polysorbate to form a first solution; (b) adding the first solution into a second solution and a pharmaceutically acceptable excipient, wherein the second solution comprises water or SLS, and a volume ratio of the first solution and the second solution is between 8:1 and 1:1; and (c) drying and compressing the mixture in step (b) to form a very slightly soluble drug with solid composition.Type: ApplicationFiled: March 28, 2016Publication date: December 29, 2016Inventors: Fang-Yu Lee, Fu-Yung Lin
-
Publication number: 20140357688Abstract: The present invention is directed to a method for inhibiting the overexpression of EZH2 in breast cancer cells. The method comprises administering to breast cancer cells an effective amount of YC-1 (3-(5?-hydroxymethyl-2?-furyl)-1-benzyl indazole), YC-1-succinate (succinic acid mono-[5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl]ester), or a pharmaceutically acceptable salt thereof. The present invention is also directed to treating breast cancer comprising administering to a subject an effective amount of YC-1-succinate.Type: ApplicationFiled: May 28, 2014Publication date: December 4, 2014Applicant: Yung Shin Pharm. Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Fang-Yu Lee, Che-Ming Teng, Ling-Chu Chang, Yung-Luen Yu
-
Patent number: 7767707Abstract: A fused pyrazolyl compound having an anti-tumor potency of the following formula is synthesized: wherein A is in which n is 0, 1, 2, or 3; Ar1 is benzene, thiophene or furan; Ar2 is furyl; and Ar3 is phenyl; R1 and R2 independently are hydrogen, halogen or —(CH2)mORe; R3 is hydrogen or alkyl; R4 is —(CH2)r-A1, wherein r is an integer of 1-5, and A1 has a formula of —O—C(O)—(CRcH)q—NRc?Rd?; R5 and R6 independently are hydrogen, halogen, or alkyl, or R5 and R6 together are —O(CH2)mO—; Rc is H, halogen, nitro, cyano, alkyl, or aryl; Re is H, alkyl, or aryl; Rc? and Rd? independently are H, alkyl, or aryl; m is 0, 1, 2, 3, 4, 5, or 6; and q is 1, 2, 3, 4, 5, or 6; or a salt thereof.Type: GrantFiled: November 13, 2008Date of Patent: August 3, 2010Assignee: Yung Shin Pharm. Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Che-Ming Teng, Fang-Yu Lee
-
Patent number: 7754751Abstract: A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R1, R2, R3, R4, R5, and R6, independently, is R?, nitro, halogen, —C(O)—OR?, —C(O)—SR?, —C(O)—NR?R?, —(CH2)mOR?, —(CH2)mSR?, —(CH2)mNR?R?, —(CH2)mCN, —(CH2)mC(O)—OR?, —(CH2)mC(O)H, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are —O(CH2)nO—, in which each of R? and R?, independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-?B with such a compound.Type: GrantFiled: March 15, 2005Date of Patent: July 13, 2010Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Che-Ming Teng, Jih-Hwa Guh, Shiow-Lin Pan, Sheng-Chu Kuo, Fang-Yu Lee
-
Publication number: 20090131681Abstract: A fused pyrazolyl compound having an anti-tumor potency of the following formula is synthesized: wherein A is in which n is 0, 1, 2, or 3; Ar1 is benzene, thiophene or furan; Ar2 is furyl; and Ar3 is phenyl; R1 and R2 independently are hydrogen, halogen or —(CH2)mORe; R3 is hydrogen or alkyl; R4 is —(CH2)r-A1, wherein r is an integer of 1-5, and A1 has a formula of —O—C(O)—(CRcH)q—NRc?Rd?; R5 and R6 independently are hydrogen, halogen, or alkyl, or R5 and R6 together are —O(CH2)mO—; Rc is H, halogen, nitro, cyano, alkyl, or aryl; Re is H, alkyl, or aryl; Rc? and Rd? independently are H, alkyl, or aryl; m is 0, 1, 2, 3, 4, 5, or 6; and q is 1, 2, 3, 4, 5, or 6; or a salt thereof.Type: ApplicationFiled: November 13, 2008Publication date: May 21, 2009Applicant: YUNG SHIN PHARM. IND. CO., LTD.Inventors: Sheng-Chu Kuo, Che-Ming Teng, Fang-Yu Lee
-
Patent number: 7514465Abstract: Novel compounds of 2-(substituted arylmethyl)-3-(substituted phenyl)-2H-indazoles and 1-(substituted arylmethyl)-3-(substituted phenyl)-1H-indazoles are synthesized, and useful as anti-angiogenic agents.Type: GrantFiled: November 15, 2005Date of Patent: April 7, 2009Assignee: Yung Shin Pharm. Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Li-Jiau Huang, Fang-Yu Lee, Che-Ming Teng, Mei-Ling Shih, Hua-Sin Chen
-
Patent number: 7378532Abstract: A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.Type: GrantFiled: November 29, 2004Date of Patent: May 27, 2008Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Fang-Yu Lee, Che-Ming Teng, Li-Jiau Huang, Li-Chen Chou, Jih-Hwa Guh, Shiow-Lin Pan
-
Patent number: 7361683Abstract: The present invention provides an injectable pharmaceutical composition containing, as an active ingredient, paclitaxel, an anti-cancer agent. The injectable pharmaceutical composition comprises an effective amount of paclitaxel, which is dissolved in polyoxyethylated castor oil, alcohol, and an injectable aqueous solution. A sufficient amount of CO2 is added to stabilize paclitaxel in the injectable pharmaceutical composition to make the injectable pharmaceutical composition to a pH about 5.0.Type: GrantFiled: November 24, 2004Date of Patent: April 22, 2008Assignee: Yung Shin Pharm. Ind., Co., LtdInventors: Fang-Yu Lee, Shan-Chiung Chen, Bin-Ken Chen, Chiung-Ju Tsai, Yuan-Ken Lin
-
Patent number: 7345079Abstract: Disclosed in this invention is a method of treating a disorder associated with low cGMP levels. The method includes administering to a subject in need thereof an effective amount of a compound having a pyrazolyl core, a first aryl group bonded to 3-C of the pyrazolyl core, and a second aryl group fused at 4-C and 5-C of the pyrazolyl core. Also disclosed are pharmaceutical compositions containing these compounds.Type: GrantFiled: December 19, 2002Date of Patent: March 18, 2008Assignee: Yung Shin Pharmaceuticals Industrial Co., LtdInventors: Che-Ming Teng, Fang-Yu Lee, Sheng-Chu Kuo
-
Publication number: 20080057255Abstract: A recordable medium includes an inscription layer and at least one contrast inverting layer. The inscription layer has at least a first sub-layer and a second sub-layer that combine upon application of a write power. The inscription layer has a reflectivity R1 with respect to a read beam before application of the write power and a reflectivity R2 after application of the write power, and R1<R2. The at least one contrast inverting layer does not combine with the first and second sub-layers of the inscription layer upon application of the write power. The at least one contrast inverting layer and the inscription layer together have a reflectivity R3 before application of the write power and a reflectivity R4 after application of the write power, and R3>R4.Type: ApplicationFiled: October 20, 2005Publication date: March 6, 2008Applicant: Lanyo Technology Co., Ltd.Inventors: Geoffrey Shuy, Cheng-Ji Lu, Hsin-Cheng Lai, Fang-Yu Lee, Yu-Yang Chang
-
Publication number: 20080057257Abstract: A recordable medium includes an inscription layer and a contrast enhancing layer. The inscription layer has at least two sub-layers that combine upon application of a write power, the inscription layer having a reflectivity R1 before application of the write power and a reflectivity R2 after application of the write power. The contrast enhancing layer does not combine with the sub-layers of the inscription layer upon application of the write power. The contrast enhancing layer and the inscription layer together have a reflectivity R3 before application of the write power and a reflectivity R4 after application of the write power, and |R4?R3|>|R2?R1|.Type: ApplicationFiled: October 20, 2005Publication date: March 6, 2008Applicant: Lanyo Technology Co., Ltd.Inventors: Geoffrey Shuy, Cheng-Ji Lu, Hsin-Cheng Lai, Fang-Yu Lee, Ko-Fu Yen
-
Publication number: 20070149554Abstract: A method for treating cancer, which includes administrating to a subject in need thereof an effective amount of a chemotherapeutic agent and an effective amount of a compound of the formula: in which, A is H or each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH?NOR, (CH2)mC(O)N(OR)R?, N(OR)R?, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: December 21, 2006Publication date: June 28, 2007Applicant: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Sheng-Chu Kuo, Che-Ming Teng, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Publication number: 20070148240Abstract: The present invention provides oral pharmaceutical formulation for azole antimicrobial drugs such as itraconazole, saperconazole, ketoconazole, and fluconazole. The oral pharmaceutical formulation contains a core and a drug coating layer. The drug coating layer contains the azole antimicrobial drug and a binder, but not containing an emulsion (such as polyoxypropylene-polyoxyethylene block copolymers, polyoxyethylene-sorbitan-fatty acid esters, sodium lauryl sulfate, or vitamin E polyethylene glycol succinate) and/or an absorbent aid (such as DL-malic acid, citric acid, ascorbic acid, and alginic acid). The oral pharmaceutical formulation can optionally contain a protective layer, such as polyethylene glycol 20,000. The present invention also provides a method for preparing and using the formulation.Type: ApplicationFiled: December 23, 2005Publication date: June 28, 2007Inventors: Fang-Yu Lee, Shan-Chiung Chen, Bin-Ken Chen, Han-Chiang Kuo
-
Publication number: 20070142449Abstract: A method for treating an angiogenesis-related disorder or cancer. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR?, (CH2)mOR, (CH2)mSR, (CH2)mNRR?, (CH2)mCN, (CH2)mC)O)OR, (CH2)mCHO, (CH2)mCH?NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R?, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.Type: ApplicationFiled: January 3, 2007Publication date: June 21, 2007Applicant: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Che-Ming Teng, Sheng-Chu Kuo, Fang-Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
-
Publication number: 20070092684Abstract: A recordable medium includes an inscription layer and a contrast enhancing layer. The inscription layer has at least two sub-layers that combine upon application of a write power, the inscription layer having a reflectivity R1 before application of the write power and a reflectivity R2 after application of the write power. The contrast enhancing layer does not combine with the sub-layers of the inscription layer upon application of the write power. The contrast enhancing layer and the inscription layer together have a reflectivity R3 before application of the write power and a reflectivity R4 after application of the write power, and |R4?R3|>|R2?R1|.Type: ApplicationFiled: October 20, 2005Publication date: April 26, 2007Inventors: Geoffrey Wen-Tai Shuy, Cheng-Ji Lu, Hsin-Cheng Lai, Fang-Yu Lee, Ko-Fu Yen
-
Publication number: 20070092682Abstract: A recordable medium includes an inscription layer and at least one contrast inverting layer. The inscription layer has at least a first sub-layer and a second sub-layer that combine upon application of a write power. The inscription layer has a reflectivity R1 with respect to a read beam before application of the write power and a reflectivity R2 after application of the write power, and R1<R2. The at least one contrast inverting layer does not combine with the first and second sub-layers of the inscription layer upon application of the write power. The at least one contrast inverting layer and the inscription layer together have a reflectivity R3 before application of the write power and a reflectivity R4 after application of the write power, and R3>R4.Type: ApplicationFiled: October 20, 2005Publication date: April 26, 2007Inventors: Geoffrey Shuy, Cheng-Ji Lu, Hsin-Cheng Lai, Fang-Yu Lee, Yu-Yang Chang